13,520 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Kazazian Asset Management LLC

Kazazian Asset Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,520 shares of the company's stock, valued at approximately $371,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Janus Henderson Group PLC raised its position in BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company's stock valued at $122,658,000 after purchasing an additional 505,481 shares during the last quarter. First Turn Management LLC bought a new position in BridgeBio Pharma in the third quarter valued at about $10,178,000. Erste Asset Management GmbH bought a new position in BridgeBio Pharma in the third quarter valued at about $3,497,000. Massachusetts Financial Services Co. MA raised its position in BridgeBio Pharma by 23.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 737,367 shares of the company's stock valued at $18,773,000 after purchasing an additional 139,104 shares during the last quarter. Finally, Exome Asset Management LLC raised its position in BridgeBio Pharma by 167.4% in the third quarter. Exome Asset Management LLC now owns 211,000 shares of the company's stock valued at $5,372,000 after purchasing an additional 132,093 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,148 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the transaction, the chief financial officer now owns 102,464 shares in the company, valued at $3,705,098.24. This trade represents a 3.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil Kumar sold 326,932 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares in the company, valued at $194,932,279.35. This represents a 5.74 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,579,739 shares of company stock valued at $323,171,901. Company insiders own 24.66% of the company's stock.

Remove Ads

BridgeBio Pharma Trading Up 2.5 %

NASDAQ BBIO traded up $0.86 during trading hours on Friday, hitting $34.77. 3,460,757 shares of the company's stock were exchanged, compared to its average volume of 2,127,431. The stock has a 50-day simple moving average of $34.08 and a 200 day simple moving average of $29.09. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The firm has a market cap of $6.61 billion, a price-to-earnings ratio of -12.20 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

BBIO has been the subject of several research reports. Bank of America increased their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, November 25th. Citigroup increased their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Evercore ISI increased their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Monday, December 23rd. HC Wainwright reissued a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Finally, Scotiabank increased their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $52.20.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.